No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Teva & Alvotech Launch US Adalimumab Biosimilar
On 20 May 2024, Teva and Alvotech announced that their interchangeable high concentration citrate-free adalimumab biosimilar Simlandi® (adalimumab-ryvk, AVT02) is now available in the US. Simlandi® is indicated for rheumatoid arthritis, juvenile idiopathic arthritis,...